Hemostemix Inc. (HEM.V)
CAD 0.1
(0.0%)
CAD 0.1
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.15 Million CAD | -57.49% |
| 2022 | 4.57 Million CAD | -31.22% |
| 2021 | 6.65 Million CAD | -10.86% |
| 2020 | 7.46 Million CAD | 58.99% |
| 2019 | 4.69 Million CAD | -26.89% |
| 2018 | 6.42 Million CAD | 128.56% |
| 2017 | 2.81 Million CAD | -24.28% |
| 2016 | 3.71 Million CAD | -6.79% |
| 2015 | 3.98 Million CAD | -7.25% |
| 2014 | 4.29 Million CAD | 180.1% |
| 2013 | 1.53 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 364.06 Thousand CAD | 11.77% |
| 2024 Q1 | 325.71 Thousand CAD | 187.73% |
| 2023 Q1 | 1.13 Million CAD | 81.13% |
| 2023 Q4 | 113.2 Thousand CAD | -72.76% |
| 2023 Q3 | 415.54 Thousand CAD | -15.75% |
| 2023 FY | 2.15 Million CAD | -52.89% |
| 2023 Q2 | 493.25 Thousand CAD | -56.4% |
| 2022 Q1 | 1.33 Million CAD | -62.29% |
| 2022 FY | 4.57 Million CAD | -31.22% |
| 2022 Q2 | 1.58 Million CAD | 18.78% |
| 2022 Q3 | 1.03 Million CAD | -34.45% |
| 2022 Q4 | 624.58 Thousand CAD | -39.87% |
| 2021 Q2 | 1.11 Million CAD | 67.84% |
| 2021 Q4 | 3.53 Million CAD | 164.17% |
| 2021 Q1 | 664.2 Thousand CAD | -82.81% |
| 2021 Q3 | 1.33 Million CAD | 20.13% |
| 2021 FY | 6.65 Million CAD | -10.86% |
| 2020 FY | 7.46 Million CAD | 58.99% |
| 2020 Q4 | 3.86 Million CAD | 165.75% |
| 2020 Q3 | 1.45 Million CAD | -28.99% |
| 2020 Q2 | 2.04 Million CAD | 1892.98% |
| 2020 Q1 | 102.7 Thousand CAD | -81.45% |
| 2019 FY | 4.69 Million CAD | -26.89% |
| 2019 Q3 | 1.29 Million CAD | -0.85% |
| 2019 Q2 | 1.3 Million CAD | -15.06% |
| 2019 Q4 | 553.71 Thousand CAD | -57.28% |
| 2019 Q1 | 1.53 Million CAD | -17.29% |
| 2018 FY | 6.42 Million CAD | 128.56% |
| 2018 Q4 | 1.86 Million CAD | 14.33% |
| 2018 Q2 | 1.73 Million CAD | 44.16% |
| 2018 Q1 | 1.2 Million CAD | 472.3% |
| 2018 Q3 | 1.62 Million CAD | -6.08% |
| 2017 Q2 | 474.07 Thousand CAD | -11.67% |
| 2017 Q4 | -322.86 Thousand CAD | -112.44% |
| 2017 Q3 | 2.59 Million CAD | 447.67% |
| 2017 FY | 2.81 Million CAD | -24.28% |
| 2017 Q1 | 536.71 Thousand CAD | -35.41% |
| 2016 FY | 3.71 Million CAD | -6.79% |
| 2016 Q2 | 627.59 Thousand CAD | -5.33% |
| 2016 Q3 | 1.58 Million CAD | 153.3% |
| 2016 Q4 | 831.01 Thousand CAD | -47.73% |
| 2016 Q1 | 662.94 Thousand CAD | -42.78% |
| 2015 Q1 | 876.34 Thousand CAD | -59.47% |
| 2015 FY | 3.98 Million CAD | -7.25% |
| 2015 Q4 | 1.15 Million CAD | 17.23% |
| 2015 Q3 | 988.34 Thousand CAD | 3.13% |
| 2015 Q2 | 958.35 Thousand CAD | 9.36% |
| 2014 FY | 4.29 Million CAD | 180.1% |
| 2014 Q1 | 9519.00 CAD | -40.39% |
| 2014 Q3 | 833.7 Thousand CAD | 2142.1% |
| 2014 Q2 | 37.18 Thousand CAD | 290.63% |
| 2014 Q4 | 2.16 Million CAD | 159.34% |
| 2013 Q3 | 16.76 Thousand CAD | -52.62% |
| 2013 FY | 1.53 Million CAD | 0.0% |
| 2013 Q1 | 51.84 Thousand CAD | 0.0% |
| 2013 Q4 | 15.97 Thousand CAD | -4.76% |
| 2013 Q2 | 35.39 Thousand CAD | -31.73% |
| 2012 Q3 | - CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Arch Biopartners Inc. | 3.22 Million CAD | 33.148% |
| Covalon Technologies Ltd. | 14.36 Million CAD | 84.983% |
| Universal Ibogaine Inc. | 5.81 Million CAD | 62.924% |
| Kane Biotech Inc. | 3.46 Million CAD | 37.79% |
| MedMira Inc. | 1.5 Million CAD | -42.887% |
| Marvel Biosciences Corp. | 2.31 Million CAD | 6.994% |
| NervGen Pharma Corp. | 17.77 Million CAD | 87.868% |
| XORTX Therapeutics Inc. | 6.38 Million CAD | 66.205% |